Tuğba Başoğlu (@tugbawitter) 's Twitter Profile
Tuğba Başoğlu

@tugbawitter

Associate professor medical oncologist/Evidence based cancer updates/fighting cancer with science

ID: 1479337496

calendar_today03-06-2013 09:58:06

72 Tweet

77 Takipçi

124 Takip Edilen

Tuğba Başoğlu (@tugbawitter) 's Twitter Profile Photo

🚨 New in nature (Oct 2025): mRNA vaccines = new immune adjuvants? 💉 Receiving a COVID-19 mRNA vaccine within 100 days of starting immune checkpoint inhibitors (ICIs) nearly doubles overall survival in NSCLC & melanoma patients. Mechanism? IFN-I surge + PD-L1 upregulation =

Tuğba Başoğlu (@tugbawitter) 's Twitter Profile Photo

🌟Excellent table summarizing the essential advances in breast cancer — from molecular profiling to targeted therapies. Clear, comprehensive, and clinically relevant.

Tuğba Başoğlu (@tugbawitter) 's Twitter Profile Photo

🚨Nature Oncology news 🧬 HER2DX brings precision to geriatric HER2+ breast cancer. In the Trans-RESPECT study, this 27-gene assay proved independently prognostic in women aged 70–80. ✨ 74% were low-risk with excellent 10-year OS (85.9%) on trastuzumab ± endocrine therapy —

Mustafa Özdoğan, MD (@ozdogan_md) 's Twitter Profile Photo

#FDA has granted traditional approval to tarlatamab-dlle (Imdelltra) for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. A meaningful step forward for a population long in need of more effective

#FDA has granted traditional approval to tarlatamab-dlle (Imdelltra) for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.

A meaningful step forward for a population long in need of more effective
Tuğba Başoğlu (@tugbawitter) 's Twitter Profile Photo

🚨 FDA Approval Alert – A New Era in Muscle-Invasive Bladder Cancer! The FDA has approved Perioperative Pembrolizumab + Enfortumab Vedotin for cisplatin-ineligible MIBC.

🚨 FDA Approval Alert – A New Era in Muscle-Invasive Bladder Cancer!
The FDA has approved Perioperative Pembrolizumab + Enfortumab Vedotin for cisplatin-ineligible MIBC.
Tuğba Başoğlu (@tugbawitter) 's Twitter Profile Photo

HER2 targeting beyond breast & gastric: Zanidatamab shows a remarkable mOS 18.1 months in metastatic BTC. 🔬 Zanidatamab is expanding across HER2-driven tumors. Already active in breast 🩷 and gastric/GEJ 💛 cancers — now delivering meaningful benefit in biliary tract cancer 💚.

HER2 targeting beyond breast & gastric: Zanidatamab shows a remarkable mOS 18.1 months in metastatic BTC.
🔬 Zanidatamab is expanding across HER2-driven tumors.
Already active in breast 🩷 and gastric/GEJ 💛 cancers — now delivering meaningful benefit in biliary tract cancer 💚.
Tuğba Başoğlu (@tugbawitter) 's Twitter Profile Photo

🌟These outcomes are hard to ignore. Adjuvant carboplatin delivering such a strong survival benefit in early TNBC could meaningfully change how we treat our patients #SABCS25 OncoDaily

Tuğba Başoğlu (@tugbawitter) 's Twitter Profile Photo

🚨 SABCS25 Key Takeaway: Alcohol Directly Increases Breast Cancer Risk New data shared at #SABCS25 reinforce a clear message: The more alcohol consumed — especially binge drinking — the higher the breast cancer risk. ✔️ Binge drinking = strongest association, particularly in

🚨 SABCS25 Key Takeaway: Alcohol Directly Increases Breast Cancer Risk

New data shared at #SABCS25 reinforce a clear message:
 The more alcohol consumed — especially binge drinking — the higher the breast cancer risk.
✔️ Binge drinking = strongest association, particularly in
Tuğba Başoğlu (@tugbawitter) 's Twitter Profile Photo

📢Less treatment, better outcomes. ctDNA-guided de-escalation in ER+/HER2– metastatic breast cancer shows longer PFS with no chemotherapy. Precision oncology is redefining value. #SABCS2025 #BreastCancer #ctDNA #PrecisionOncology

Tuğba Başoğlu (@tugbawitter) 's Twitter Profile Photo

🚨 BREAKING: The Standard of Care Has Changed!The FDA has approved Niraparib + Abiraterone for BRCA2-mutated mCSPC. With a 54% risk reduction, we are no longer waiting for resistance. Precision medicine is now the front line. @oncodailiy @larvol U.S. FDA #FDA #Oncology #BRCA2

🚨 BREAKING: The Standard of Care Has Changed!The FDA has approved Niraparib + Abiraterone for BRCA2-mutated mCSPC. With a 54% risk reduction, we are no longer waiting for resistance. Precision medicine is now the front line. 
@oncodailiy @larvol <a href="/US_FDA/">U.S. FDA</a>  #FDA #Oncology #BRCA2